经导管主动脉瓣置换术治疗单纯性主动脉瓣反流:随机SEASON-AR临床试验
SEASON-AR试验在中国18家中心纳入210例外科手术困难或拒绝手术的严重单纯性主动脉瓣反流患者,随机接受经股动脉TAVR(VitaFlow系统)联合GDMT或单用GDMT。1年时TAVR组主要终点(全因死亡、致残性卒中或心衰再住院)显著低于GDMT组(8.3% vs 24.8%;HR 0.31,95%CI 0.14-0.66;P=0.001),主要由心衰再住院减少驱动(3.7% vs 21.3%;HR 0.16,95%CI 0.06-0.47;P<0.001)。TAVR组大出血或危及生命出血及新发永久起搏器植入率更高,多发生在术后30天内。
要点
- 对外科手术困难或拒绝手术的严重单纯AR患者,TAVR联合GDMT较单用GDMT显著降低1年主要复合终点。
- 获益主要来自心衰再住院减少(3.7% vs 21.3%;HR 0.16)。
- TAVR组大出血或危及生命出血及新发永久起搏器植入增加,多发生于术后30天内。
核心结论
- 在严重单纯性主动脉瓣反流患者中,TAVR联合GDMT较单用GDMT显著降低1年全因死亡、致残性卒中或心衰再住院复合终点,但术后30天内大出血或危及生命出血及新发永久起搏器植入率更高。
研究设计与样本
- 前瞻性、研究者发起、多中心、随机、开放标签试验,在中国18家中心纳入210例严重单纯性主动脉瓣反流患者。
- 患者因外科手术困难、不可接受或持续拒绝手术入组,按1:1随机接受经股动脉TAVR(VitaFlow系统)联合GDMT(n=109)或单用GDMT(n=101)。
主要发现
- 1年主要终点(全因死亡、致残性卒中或心衰再住院)Kaplan-Meier估计TAVR组8.3% vs GDMT组24.8%(HR 0.31,95%CI 0.14-0.66;P=0.001)。
- 心衰再住院TAVR组3.7% vs GDMT组21.3%(HR 0.16,95%CI 0.06-0.47;P<0.001)。
- TAVR组大出血或危及生命出血及新发永久起搏器植入率更高,多发生在术后30天内。
关键数值与推荐
- 主要终点为1年全因死亡、致残性卒中或心衰再住院复合终点。
- TAVR组主要终点8.3% vs GDMT组24.8%,HR 0.31(95%CI 0.14-0.66),P=0.001。
- 心衰再住院TAVR组3.7% vs GDMT组21.3%,HR 0.16(95%CI 0.06-0.47),P<0.001。
- TAVR组大出血或危及生命出血及新发永久起搏器植入率更高,多数发生于术后30天内。
临床怎么用
- 对外科手术困难或拒绝手术的严重单纯性主动脉瓣反流患者,可考虑经股动脉TAVR联合GDMT以降低1年死亡、致残性卒中或心衰再住院风险。
- 术后30天内需重点监测大出血或危及生命出血及新发永久起搏器植入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with severe pure aortic regurgitation (AR) at high surgical risk, guideline-directed medical therapy (GDMT) is often the only available option. Transfemoral transcatheter aortic valve replacement (TAVR) is an established treatment for aortic stenosis and has also been evaluated in patients with pure AR. However, no adequately powered randomized trial has compared TAVR with GDMT alone in this population. METHODS: We conducted a prospective, investigator-initiated, multicenter, randomized, open-label trial in China. Patients with severe pure AR for whom surgery was considered difficult or unacceptable by the local heart team or who persistently declined surgery were randomly assigned at a 1:1 ratio to receive transfemoral TAVR with the VitaFlow system plus GDMT or GDMT alone. The primary end point was a composite of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year. RESULTS: We assigned 210 patients with severe pure AR to the TAVR group (n=109) or GDMT group (n=101) at 18 centers. At 1-year follow-up, the Kaplan-Meier estimate of the primary end point was significantly lower in the TAVR group than in the GDMT group (8.3% vs 24.8%; hazard ration [HR], 0.31 [95% CI, 0.14-0.66]; P=0.001), driven primarily by a reduction in heart failure rehospitalization (3.7% vs 21.3%; HR, 0.16 [95% CI, 0.06-0.47]; P < 0.001). TAVR was associated with higher rates of major or life-threatening bleeding and new permanent pacemaker implantation, most of which occurred within 30 days after the procedure. CONCLUSIONS: Among patients with severe pure AR, TAVR plus GDMT significantly reduced the rate of all-cause death, disabling stroke, or heart failure rehospitalization at 1 year compared with GDMT alone despite higher 30-day rates of major or life-threatening bleeding and new permanent pacemaker implantation. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04864145.
引用
- Gao XF, Wang Y, Jiang H, et al. Transcatheter Aortic Valve Replacement in Pure Aortic Regurgitation: The Randomized SEASON-AR Clinical Trial. Circulation. 2026. PMID: 42965504. doi:10.1161/CIRCULATIONAHA.126.082827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。